Retrospective Study on Microbial Diversity in Paraffin Tissue of Pancreatic Diseases

Overview

The great harm of pancreatic diseases and the unknown etiology and pathogenesis make it difficult to intervene in most early cases in time. Previous studies by scholars and applicants at home and abroad have shown that the microflora in pancreatic tissue is closely related to chronic pancreatitis and pancreatic cancer. However, the research on the mechanism of microbial diversity in pancreatic tissue and the occurrence and development of various pancreatic diseases has not been reported. Based on the previous research, this subject continues to take various pancreatic diseases as the research object based on the database of pancreatic center and pathology department of Ruijin Hospital Affiliated to Medical College of Shanghai Jiaotong University, To explore the characteristics of microbial flora in pancreas in different pancreatic diseases and its mechanism of influence on disease microenvironment. Select specific microbial flora or targets in the pancreas for various pancreatic diseases, so as to provide new theoretical basis and practical guidance for the early diagnosis and treatment of pancreatic diseases.

Full Title of Study: “Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197 Ruijin Road II, Shanghai 200025, China”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: December 31, 2022

Detailed Description

AIMS: To explore the correlation between the characteristics of microbial flora in pancreas and clinical and pathological characteristics of patients with various pancreatic diseases; To clarify the similarities and differences of microbial flora in pancreas in different pancreatic diseases; Select the specific microbial flora or targets in the pancreas for various pancreatic diseases; To provide a new theoretical basis and practical guidance for the early diagnosis, treatment and prognosis of pancreatic diseases. METHODS: (1)Patients with various pancreatic diseases operated from January 2005 to June 2019, including but not limited to: pancreatic ductal adenocarcinoma, chronic pancreatitis, pancreatic serous cystadenoma, pancreatic mucinous cystadenoma, intraductal papillary mucinous tumor, pancreatic neuroendocrine tumor, pancreatic acinar cell carcinoma, solid pseudopapillary tumor of pancreas and other pancreatic diseases. (2) According to the database of Ruijin Hospital, about 30 age and sex matched cases were selected for each pancreatic disease. (3) All the participants provided written informed consent for participating in the study. If the patient dies, there is an ethical exemption. The collecting procedures have no intervention or impact on treatment measures. (4)The lesion tissue and adjacent pancreatic tissue were obtained from the paraffin tissue made from the surgical specimens for sampling. (5)High throughput sequencing was performed according to the instructions of 16S rRNA gene sequencing kit or macro gene detection kit. Anosim (analysis of similarities) statistical method was used for similarity analysis to analyze the correlation between microbiota differences and patients' clinical characteristics (including but not limited to various clinical symptoms, serological indexes, tumor stage, prognosis, and human whole exon sequencing, etc.), pathological type and grade, whether to transfer or not. (6)According to the instructions of immunohistochemical detection and immunofluorescence detection, the relative abundance and localization of microorganisms in different pancreatic tissues of different pancreatic diseases in different cells (tumor cells, immune cells, normal pancreatic acinar cells, duct cells, etc.) were detected.

Interventions

  • Other: No any intervention
    • have no any intervention

Arms, Groups and Cohorts

  • Pancreatic ductal adenocarcinoma
    • According to the relevant information such as clinical features and prognosis, it may continue to be divided into several subgroups.
  • Chronic pancreatitis
    • According to the relevant information such as clinical features and prognosis, it may continue to be divided into several subgroups.
  • Pancreatic serous cystadenoma
    • According to the relevant information such as clinical features and prognosis, it may continue to be divided into several subgroups.
  • Pancreatic mucinous cystadenoma
    • According to the relevant information such as clinical features and prognosis, it may continue to be divided into several subgroups.
  • Intraductal papillary mucinous tumor
    • According to the relevant information such as clinical features and prognosis, it may continue to be divided into several subgroups.
  • Pancreatic neuroendocrine tumor
    • According to the relevant information such as clinical features and prognosis, it may continue to be divided into several subgroups.
  • Pancreatic acinar cell carcinoma
    • According to the relevant information such as clinical features and prognosis, it may continue to be divided into several subgroups.
  • Solid pseudopapillary tumor of pancreas
    • According to the relevant information such as clinical features and prognosis, it may continue to be divided into several subgroups.
  • Blank paraffin section

Clinical Trial Outcome Measures

Primary Measures

  • 16sRNA and metagenomics
    • Time Frame: 7/2026
    • To obtain intestinal microbial information in patients with pancreatic cancer and other pancreatic diseases, to obtain microbial community structure, evolutionary relationship and information on microbial and environmental correlation in the intestinal environmental samples (weight unit: gram). The patient’s microbiological characteristics were correlated with the patient’s clinical characteristics and prognosis, so as to obtain the relevant biomarker information.

Participating in This Clinical Trial

Inclusion Criteria

  • Age ≥ 5 years old, ≤ 75 years old; – After MDT discussion, routine surgery can be performed, and the postoperative pathology is clear as pancreatic cancer and other pancreatic diseases; – No history of antibiotics for three months before surgery, no history of yogurt containing probiotics – There is no serious damage to heart, liver and kidney function. Exclusion Criteria:

  • Antibiotics or yogurt containing probiotics history in three months; – Patients with evidence of sensory or motor neuropathy; – Those who have a clear cardiovascular disease, severe associated disease or active infection, including known HIV infection; – Those who have a history of other cancers.

Gender Eligibility: All

Minimum Age: 5 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Ruijin Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: WeiWang, Chief physician – Ruijin Hospital
  • Overall Official(s)
    • Wei Wang, Dr., Study Chair, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University,No. 197 Ruijin Road II
  • Overall Contact(s)
    • Wei Wang, Dr., +86- 13761648121, wangwei_0306@163.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.